Jefferies Downgrades ResMed (RMD) to Underperform; AirSense10 Cycle Waning
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies downgraded ResMed (NYSE: RMD) from Hold to Underperform with a price target of $58.00 (from $60.00), saying the AirSense10 Cycle is waning.
Analyst Anthony Petrone commented, "We conducted a DME survey and several expert calls to gauge the latest CPAP trends. AirSense10 is still considered best-in-class, but Dream has closed the gap while being priced at a discount. Lower Medicare rates effective July 1, 2016 are pressuring private rates and are expected to lead to further DME consolidation and price pressure. Downgrading to UP as cycles evolve."
Shares of ResMed closed at $69.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Seaport Global Securities Upgrades Flowserve Corp. (FLS) to Buy
- CytoSorbents (CTSO) PT Raised to $10 at Maxim Group
- RBC Capital Reiterates Outperform on General Electric (GE) Following 4Q
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Downgrades
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!